Bronchodilators Market is Progressing Towards a Strong Growth by 2025

Bronchodilators are drugs used by people suffering with asthma. These drugs help open the airway passages. These are also used for expanding the wind pipe, thus improving the breathing of the individuals suffering from lung infections, bronchial asthma, and chronic obstructive pulmonary disease (COPD).

There are two forms of bronchodilators: short acting bronchodilators and long acting bronchodilators. The short acting bronchodilators provide quick relief from asthma and can be used on a daily basis. The long acting bronchodilators assist in controlling the symptoms of asthma by opening the air passage for up to 12 hours. Short acting bronchodilators include albuterol (a generic solution for nebulizers), metaproterenol, pirbuterol, and levalbuterol.

Long acting bronchodilators include advair, symbicort, and dulera which is a combination of beta agonist bronchodilator and a steroid. Major side effects of bronchodilators include increased heart rate, muscle cramps, inappropriate sleeping pattern, upset stomach, and others. According to the Centers for Disease and Control of Infection reports published in 2014, the number of adults who were diagnosed with asthma was 17.7 million, out of which, there were 3,651 deaths due to asthma, and women were the most affected. According the World Health Organization, in 2012, more than three million people died due to COPD, which was 6% of all deaths globally.

Request Report TOC @ https://www.transparencymarketresearch.com/bronchodilators-market.html

There are three types of bronchodilator used for treating respiratory diseases: beta-agonist, anticholinergic, and theophylline. These types are available in different forms based on route of administration such as inhaler, tablet, liquid, and injectable. Inhaler is the most preferred form of administration for using beta-agonist and anticholinergic. A major disadvantage of long acting beta agonist bronchodilator is that it increases the risk of asthma death; therefore, it should be used only as an added treatment for individuals or patients who use steroid. Anticholinergics are used for treating patients suffering from COPD and asthma. Atrovent, an anticholinergic bronchodilator, is used for the treatment of COPD. It is administered using an inhaler or a nebulizer. Tiotropium bromide is a long acting anticholinergic inhaler, which is used for treating patients suffering from asthma and COPD.

The global bronchodilators market has been segmented based on form of bronchodilator, route of administration, drug class, distribution channel, and region. In terms of form of bronchodilator, the global market is divided into short acting bronchodilators and long acting bronchodilators. Based on route of administration, the market is segmented into oral, injectable, and nasal. In terms of drug class, the market is divided into adrenergic bronchodilators, anticholinergic bronchodilators, and others.

Request For Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35912

The major drivers for the growth of the global bronchodilators market are rising incidence rate of respiratory and pulmonary diseases such as asthma and COPD, growing awareness among individuals, increasing initiatives by governments and health care services, increasing demand for bronchodilator drugs, and adoption of unhealthy lifestyle. According to WHO reports, there is an increased use of tobacco among women in high-income countries and increased risk of exposure to indoor air pollutants in low-income countries. COPD affects men and women equally. The global burden of COPD was nearly 251 million cases in 2016. The WHO has designed a framework named WHO Framework Convention on Tobacco Control (WHO FCTC) to implement MPOWER package, which aims at assisting country level implementation of effective interventions focused on reducing the demand for tobacco.

Geographically, the global bronchodilators market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to be the largest market for bronchodilators due to high incidence rate of diseases such as COPD and asthma, high demand for bronchodilator drugs, and increase in awareness. Europe holds the second largest market share. The Asia Pacific market is expected to provide a lucrative opportunity during the forecast period due to increasing disease burden, growing biopharmaceutical industry, and rising research activity along with competitive landscape in the pharmaceutical industry. The market in Latin America and Middle East & Africa is anticipated to grow owing to increasing health care infrastructure and growing public-private collaboration to expand the health care sector.

Pre Book full report@ https://www.transparencymarketresearch.com/checkout.php?rep_id=35753<ype=S

Major companies operating in the global bronchodilators market are F. Hoffmann-La Roche, Gilead Sciences, Novartis Ag, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Inc., and AstraZeneca.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact

Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
TMR Blog: http://www.theglobalhealthnews.com/

This release was published on openPR.